Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies.
Zagouri F, Kastritis E, Zomas A, Terpos E, Katodritou E, Symeonidis A, Delimpasi S, Pouli A, Vassilakopoulos TP, Michalis E, Giannouli S, Kartasis Z, Christoforidou A, Kokoviadou K, Hatzimichael E, Gika D, Megalakaki C, Papaioannou M, Kyrtsonis MC, Konstantopoulos K, Dimopoulos MA; Greek Myeloma Study Group.
Zagouri F, et al.
Eur J Haematol. 2017 Nov;99(5):409-414. doi: 10.1111/ejh.12923. Epub 2017 Sep 26.
Eur J Haematol. 2017.
PMID: 28675766